H B5) Table Summary of studies assessing impact of delayed treatment in Population 1 Study Length of Length N [I] Disease Overall Cancer Metastases Biochemical Extra Lymph Positive Tumour delay of risk survival specific Formation recurrence capsular node surgical upgrade N [D] profile survival extension positive margins Abern et [I] <9m 5 years [I] [I] . . . 37% vs. 70% NS . 30% vs. 76% NS al. 1503 In- (intermediate (intermediate [D] >9m 48% disease only) disease only) [D] 58 [D] 43% Andrews [I] <3m 5 years [I] 633 Total: NS NS NS NS . . . . et al. [D1] 3-9 m [D1] L-42%, 623 In-39%, [D2] >9 m H-19% [D2] 62 Dall'era et [I] median Median [I] [I] 21% . . . . NS . NS NS al. 3m 27 1345 low, months 79% [D] median [D] 63 (range high 18m 1-162) [D] 52% low, high
H B5) Table Summary of studies assessing impact of delayed treatment in Population 1 Study Length of delay Length of N [I] N [D] Disease risk profile Overall survival Cancer specific survival Metastases Formation Biochemical recurrence Extra capsular extension Lymph node positive Positive surgical margins Tumour upgrade Abern et al. [I] <9m [D] >9m 5 years [I] 1503 [D] 58 [I] [D] In- 43% . . . 37% vs. 70% (intermediate disease only) NS . 30% vs. 76% (intermediate disease only) NS Andrews et al. [I] <3m [D1] 3-9 m [D2] >9 m 5 years [I] 633 [D1] 623 [D2] 62 Total: L-42%, In-39%, H-19% NS NS NS NS . . . . Dall'era et al. [I] median 3m [D] median 18m Median 27 months (range 1-162) [I] 1345 [D] 63 [I] 21% low, 79% high [D] 52% low, 48% high . . . . NS . NS NS
1397_Final_MSAC_Assessment_Report.docx